Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
GlobeNewswire
- ATH434-201 Trial on Track to Complete in November 2024 –
- Top-Line Data Expected in January 2025..
National Institute of Neurological Disorders and Stroke
News and Video Search Results
News coverage
-
Sacroiliac Joint Fusion Market To Reach USD 4,106.7 Billion By 2032 | DataHorizzon Research
GlobeNewswire
-
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
GlobeNewswire
-
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
GlobeNewswire
-
Wistar Scientists Identify Pro-aging ‘Sugar Signature’ in the Blood of People Living with HIV
GlobeNewswire
0 shares
1 views
You might like
National Institute of Neurological Disorders and Stroke media coverage
U.S. Congressman Josh Gottheimer Champions Rare Disease Research With Sponsorship of Legislative Bill - H.Res.1039 - Advocating for Increased Funding for Charcot-Marie-Tooth Disease (CMT)
Business Wire
SCARSDALE, N.Y.--(BUSINESS WIRE)-- #charcotmarietoothdisease--On February 29, 2024, International Rare Disease Day, U.S...
-
Congress Passes Bills Making Major Investments in Alzheimer’s
GlobeNewswire
-
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
GlobeNewswire
-
Global Cerebral Oximetry Monitoring Market Size To Exceed USD 425.87 Million By 2033 | CAGR of 6.98%
GlobeNewswire
-
Biotechnology Industry Insights: Comprehensive Report on Collaboration Deals from 2019-2024 Now Available
GlobeNewswire
Advertisement
More coverage
Pharmaceutical and Biotechnology Sector Insights: Comprehensive Analysis of Option and Evaluation Deals (2016-2024)
GlobeNewswire
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024" report..
-
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
GlobeNewswire
-
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
GlobeNewswire
-
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
GlobeNewswire
-
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
GlobeNewswire